Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 23, 2026 01:00 ET | Source: Sanofi Winthrop Industrie

Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses

Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapse
June 23, 2026 01:00 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse : Cenrifki (tolebrutinib) de Sanofi approuvé dans l’UE comme premier médicament ciblant la progression du handicap dans la sclérose en plaques secondairement progressive sans rechutes

Cenrifki (tolebrutinib) de Sanofi approuvé dans l’UE comme premier médicament ciblant la progression du handicap dans la sclérose en plaques secondairement